Trials / Completed
CompletedNCT01941511
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
A Phase 1, Randomized, 3-way, Crossover Single Dose, Placebo, and Active Controlled Study to Evaluate the Effect of Intravenous Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- GlycoMimetics Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of GMI-1070 in African-American Adult subjects. This is conducted as part of standard drug development.
Detailed description
Safety
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivipansel | Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV. |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-09-13
- Last updated
- 2020-06-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01941511. Inclusion in this directory is not an endorsement.